Abstract:Here we first identified a novel pyridazinone derivative, compound 3711, as a nonnucleosidic hepatitis B virus (HBV) inhibitor in a cell model system. 3711 decreased extracellular HBV DNA levels by 50% (50% inhibitory concentration [IC50]) at 1.5 ± 0.2 μM and intracellular DNA levels at 1.9 ± 0.1 μM, which demonstrated antiviral activity at levels far below those associated with toxicity. Both the 3TC/ETV dually resistant L180M/M204I mutant and the adefovir (ADV)-resistant A181T/N236T mutant were as susceptible to 3711 as wild-type HBV. 3711 treatment induced the formation of genome-free capsids, a portion of which migrated faster on 1.8% native agarose gel. The induced genome-free capsids sedimented more slowly in isopycnic CsCl gradient centrifugation without significant morphological changes. 3711 treatment decreased levels of HBV DNA contained in both secreted enveloped virion and naked virus particles in supernatant. 3711 could interfere with capsid formation of the core protein (Cp) assembly domain. A Cp V124W mutant, which strengthens capsid interdimer interactions, recapitulated the effect of 3711 on capsid assembly. Pyridazinone derivative 3711, a novel chemical entity and HBV inhibitor, may provide a new opportunity to combat chronic HBV infection.

2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1h)-one Derivatives As Anti-Hbv Agents Targeting at Capsid Assembly

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Synthesis of Janus Type Nucleoside Analogues and Their Preliminary Bioactivity

The SAR-based Development of Small Molecular HBV Capsid Assembly Modulators

Optimization and Synthesis of Pyridazinone Derivatives As Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors

Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators

Discovery Of (1h-Pyrazolo[3,4-C]Pyridin-5-Yl)Sulfonamide Analogues As Hepatitis B Virus Capsid Assembly Modulators By Conformation Constraint

Structure-Based Discovery of <i>N</i>-Sulfonylpiperidine-3-Carboxamides as Novel Capsid Assembly Modulators for Potent Inhibition of HBV Replication

Development of Benzimidazole-Based Compounds As Novel Capsid Assembly Modulators for the Treatment of HBV Infection

Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay

Pharmacophore-Based Virtual Screening and Structural Modification of Novel Benzamide Derivatives as HBV Capsid Assembly Modulators

Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators

2-Arylthio-5-iodo Pyrimidine Derivatives As Non-Nucleoside HBV Polymerase Inhibitors

A Novel Pyridazinone Derivative Inhibits Hepatitis B Virus Replication by Inducing Genome-Free Capsid Formation

3D-QSAR, molecular docking and molecular dynamics simulations analyses of a series of heteroaryldihydropyrimidine derivatives as hepatitis B virus capsid assembly inhibitors

Design, Synthesis, Molecular Modeling Studies and Biological Evaluation of N'-Arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide Derivatives as Novel Anti-HCV Agents

Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays

5-Iodo-2-arylalkylthio-6-aryl pyrimidin-4(3H)-ones as non-nucleoside anti-HBV agents

A novel phthalazinone derivative as a capsid assembly modulator inhibits hepatitis B virus expression

Synthesis and Anti‐HBV Activities Evaluation of New Ethyl 8‐imidazolylmethyl‐7‐hydroxyquinoline‐3‐carboxylate Derivatives in Vitro